UF Health Urologists Working to Expand Options for BCG-Unresponsive Bladder Cancer
“Other treatments in the bladder are typically administered once a week for six weeks,” Crispen said. “Offering longer intervals between treatments is favorable for these patients, leading to fewer office visits, co-pays, catheterizations and everything else that goes along with the process.” If successful, Crispen said new treatment agents may even replace intravesical BCG as the primary therapy for high-risk NMIBC. BCG treatments are highly toxic, with potentially serious complications; in fact, fewer than 20% of patients are able to tolerate all doses of BCG maintenance therapy.